Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sonpiretigene Isteparvovec - Nanoscope Therapeutics

Next Previous
Drug Profile

Sonpiretigene Isteparvovec - Nanoscope Therapeutics

Alternative Names: MCO-010; vMCO 1; vMCO-010

Latest Information Update: 07 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanoscope Therapeutics
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Eye protein replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease; Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Phase II Retinitis pigmentosa; Stargardt disease
  • No development reported Dry age-related macular degeneration

Most Recent Events

  • 25 Apr 2025 Nanoscope therapeutics plans a phase III registrational trial for Stargardt disease in 2025
  • 28 Feb 2025 No recent reports of development identified for preclinical development in Dry age-related macular degeneration in USA (Intravitreous, Injection)
  • 09 Jan 2025 Nanoscope Therapeutics announces intention to launch Sonpiretigene Isteparvovec for Retinitis pigmentosa

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top